Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Thymopoietin II Fragment (TP-1) (TP1) is a immune peptide, at the preclinical stage in the published literature. Active fragment of thymopoietin that modulates T-cell differentiation and immune function.
Active fragment of thymopoietin that modulates T-cell differentiation and immune function.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | Research varies |
Induces T-cell differentiation markers and modulates immune cell function.
Active fragment of thymopoietin that modulates T-cell differentiation and immune function.
Induces T-cell differentiation markers and modulates immune cell function.
Thymopoietin II Fragment (TP-1) is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.